Rezultati pretrage - Jeffrey W. Tyner

Detaljiziraj rezultate
  1. 1
    Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals

    Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals od Jeffrey W. Tyner

    Izdano 2006
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    What's different about atypical CML and chronic neutrophilic leukemia?

    What's different about atypical CML and chronic neutrophilic leukemia? od Kim-Hien T. Dao, Jeffrey W. Tyner

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  3. 3
    Genomics of chronic neutrophilic leukemia

    Genomics of chronic neutrophilic leukemia od Julia E. Maxson, Jeffrey W. Tyner

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  4. 4
    Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia

    Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia od Emmanuella Oyogoa, Elie Traer, Jeffrey W. Tyner, Curtis A. Lachowiez

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  5. 5
    The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment

    The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment od Jason Gotlib, Julia E. Maxson, Tracy I. George, Jeffrey W. Tyner

    Izdano 2013
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  6. 6
    Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia

    Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia od Shovik Bandyopadhyay, Junjie Li, Elie Traer, Jeffrey W. Tyner, Amy Zhou, Stephen T. Oh, Ji‐Xin Cheng

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia

    Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia od Vincent T. Bicocca, Bill H. Chang, Behzad Kharabi Masouleh, Markus Müschen, Marc Loriaux, Brian J. Druker, Jeffrey W. Tyner

    Izdano 2012
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  8. 8
    Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerization

    Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerizatio... od Julia E. Maxson, Samuel B. Luty, Jason D. MacManiman, Melissa L. Abel, Brian J. Druker, Jeffrey W. Tyner

    Izdano 2014
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

    Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia od Kim-Hien T. Dao, Magdolna Solti, Julia E. Maxson, Elliott F. Winton, Richard D. Press, Brian J. Druker, Jeffrey W. Tyner

    Izdano 2014
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  10. 10
    Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

    Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations od Elie Traer, Nathalie Javidi‐Sharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel English, Jacqueline Martinez, Jeffrey W. Tyner, Melissa Wong, Brian J. Druker

    Izdano 2014
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  11. 11
    Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia

    Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia od Vishesh Khanna, Scott T. Pierce, Kim‐Hien T. Dao, Cristina E. Tognon, David E. Hunt, Brian Junio, Jeffrey W. Tyner, Brian J. Druker

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  12. 12
    Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance

    Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance od Shelton A. Viola, Elie Traer, Jianya Huan, Noah I. Hornick, Jeffrey W. Tyner, Anupriya Agarwal, Marc Loriaux, Brian H. Johnstone, Peter Kurre

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Carta
    Spremi u popis
    Spremljeno u:
  13. 13
    Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

    Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma od Matthew B. Siegel, Selina Qiuying Liu, Monika A. Davare, Stephen E. Spurgeon, Marc Loriaux, Brian J. Druker, Emma C. Scott, Jeffrey W. Tyner

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  14. 14
    Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

    Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia od Haijiao Zhang, Yusuke Nakauchi, Thomas Köhnke, Melissa Stafford, Daniel Bottomly, Rozario Thomas, Beth Wilmot, Shannon K. McWeeney, Ravindra Majeti, Jeffrey W. Tyner

    Izdano 2020
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  15. 15
    FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

    FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia od Elie Traer, Jacqueline Martinez, Nathalie Javidi‐Sharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel English, Tibor Kovacsovics, Jeffrey W. Tyner, Melissa H. Wong, Brian J. Druker

    Izdano 2016
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  16. 16
    Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia

    Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia od Jessica T. Leonard, Joelle Rowley, Christopher A. Eide, Elie Traer, Brandon Hayes‐Lattin, Marc Loriaux, Stephen E. Spurgeon, Brian J. Druker, Jeffrey W. Tyner, Bill H. Chang

    Izdano 2016
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  17. 17
    Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations

    Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations od Su Lin Lim, Alisa Damnernsawad, Pavithra Shyamsunder, Wee Joo Chng, Bing Han, Liang Xu, Jian Pan, Pushkar Dakle, Serhan Alkan, Jeffrey W. Tyner, H. Phillip Koeffler

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  18. 18
    CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia

    CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia od Animesh Pardanani, Terra L. Lasho, Rebecca R. Laborde, Michelle A. Elliott, C. Hanson, Ryan A. Knudson, Rhett P. Ketterling, Julia E. Maxson, Jeffrey W. Tyner, A Tefferi

    Izdano 2013
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  19. 19
    Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

    Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance od Nathalie Javidi‐Sharifi, Elie Traer, Jacqueline Martinez, Anu Gupta, Takehiro Taguchi, Jennifer Dunlap, Michael C. Heinrich, Christopher L. Corless, Brian P. Rubin, Brian J. Druker, Jeffrey W. Tyner

    Izdano 2014
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  20. 20
    CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

    CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms od Jeffrey W. Tyner, Thomas G.P. Bumm, Jutta Deininger, Lisa J. Wood, Karl J. Aichberger, Marc Loriaux, Brian J. Druker, Christopher J. Burns, Emmanuelle Fantino, Michael W. Deininger

    Izdano 2010
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: